Document is current
Any future updates will be listed below
-
Authors
Thompson, Eric M. https://orcid.org/0000-0003-2796-9914
Ashley, David M. https://orcid.org/0000-0002-4754-5900
Ayasoufi, Katayoun
Norberg, Pamela
Archer, Gerald
Buckley, Evan D.
Herndon, James E. II
Walter, Ashley
Archambault, Bridget
Flahiff, Charlene
Jaggers, Denise
Gorski, Laura https://orcid.org/0009-0001-9346-2997
Sanchez, Luis A.
Congdon, Kendra
Hotchkiss, Kelly
Cook, Sarah L. https://orcid.org/0000-0002-0516-9388
Moelker, Eliese
Vlahovic, Gordana
Reap, Elizabeth
Schroeder, Kristin
Randazzo, Dina
Desjardins, Annick https://orcid.org/0000-0003-3869-8283
Johnson, Margaret O. https://orcid.org/0000-0003-1208-622X
Peters, Katherine
Khasraw, Mustafa https://orcid.org/0000-0003-3249-9849
Friedman, Henry https://orcid.org/0000-0001-7588-032X
Mitchell, Duane A. https://orcid.org/0000-0001-6049-213X
Sampson, John H.
Landi, Daniel
-
Funding
Funding for this research was provided by:
Pediatric Brain Tumor Foundation
- License Information
-
More Information
Article History
Received: 11 August 2024
Accepted: 8 May 2025
First Online: 12 June 2025
Competing interests
: D.A.M. and J.H.S. hold the patent to PEP-CMV (Compositions, methods and kits for eliciting an immune response, US 11,376,322). A.W. is currently employed by Day One Biopharmaceuticals, G.V. is currently employed by GSK, E.R. is currently employed by Q2 Solutions, L.A.S. is currently employed by Tune Therapeutics, and K.C. is currently employed by Tune Therapeutics. M.K. reports grants or contracts from BMS, AbbVie, BioNTech, CNS Pharmaceuticals, Daiichi Sankyo, Immorna Therapeutics, Immvira Therapeutics, JAX lab for genomic research and Personalis; received consulting fees from AnHeart Therapeutics, Berg Pharma, George Clinical, Manarini Stemline and Servier; received honoraria from GSK and is on a data safety monitoring board for BPG Bio. The other authors declare no competing interests.
